7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 
      
    		               
      cash flows from operating activities:
    		               
      net income
    		12,899,000 5,085,000 32,000 -26,795,000 -14,033,000 -12,674,000 -35,379,000 -61,731,000 -36,149,000 -75,326,000 -53,333,000 -71,541,000 -42,520,000 -58,859,000 -74,196,000 
      adjustments to reconcile net income to net cash from operating activities:
    		               
      depreciation and amortization
    		335,000 329,000 331,000 309,000 311,000 320,000 306,000 423,000 420,000 407,000 405,000 396,000 389,000 335,000 317,000 
      inventory obsolescence
    		30,000 817,000 209,000 -11,000 1,360,000   186,000 -2,000 2,000 236,000     
      stock-based compensation expense
    		18,601,000 21,304,000 21,368,000 21,339,000 17,249,000 13,173,000 13,652,000 16,488,000 12,279,000 12,841,000 14,007,000 15,282,000 9,951,000 9,867,000 9,601,000 
      payment of pharmakon pik interest
    		-3,661,000               
      non-cash interest expense on royalty financing obligations
    		12,923,000               
      non-cash interest expense on secured term loan and amortization of debt issuance costs
    		384,000               
      amortization of discount on investments
    		-707,000 -1,150,000 -1,383,000             
      loss on extinguishment of debt
    		2,740,000        0       
      gain on sale of non-financial asset
    		               
      changes in operating assets and liabilities:
    		               
      increase in receivables
    		-17,000               
      increase in inventory
    		               
      increase in prepaid expenses and other assets
    		               
      decrease in royalty financing obligations
    		-18,319,000               
      increase in accounts payable and accrued expenses
    		               
      net cash from operating activities
    		41,624,000 41,302,000 -27,517,000 -5,213,000 8,245,000 -1,368,000 -53,684,000 -8,918,000 -19,897,000 -18,814,000 -47,512,000 -23,849,000 -32,444,000 -27,757,000 -77,800,000 
      capex
    		-1,344,000 -179,000 -143,000 -675,000 -59,000 -155,000 -235,000 -554,000 -987,000 -467,000 -160,000 0 -175,000 -244,000 -406,000 
      free cash flows
    		40,280,000 41,123,000 -27,660,000 -5,888,000 8,186,000 -1,523,000 -53,919,000 -9,472,000 -20,884,000 -19,281,000 -47,672,000 -23,849,000 -32,619,000 -28,001,000 -78,206,000 
      cash flows from investing activities:
    		               
      acquisitions of property and equipment
    		-1,344,000 -179,000 -143,000 -675,000 -59,000 -155,000 -235,000 -554,000 -987,000 -467,000 -160,000  -175,000 -244,000 -406,000 
      purchases of investments
    		-58,634,000 -29,341,000 -48,762,000             
      sales and maturities of investments
    		73,000,000     110,000,000 117,000,000 129,069,000 147,995,000 66,325,000 41,688,000 77,741,000 35,655,000   
      sale of non-financial asset
    		               
      net cash from investing activities
    		13,572,000 29,127,000 27,095,000 17,797,000 8,489,000 -2,449,000 28,756,000 -28,473,000 23,119,000 -19,035,000 -107,109,000 77,215,000 -69,543,000 -97,438,000 -38,472,000 
      cash flows from financing activities:
    		               
      net proceeds from common stock issued under stock-based compensation plans
    		2,647,000 3,421,000 2,390,000 -586,000 2,085,000 264,000 1,681,000 -178,000 1,487,000 1,954,000 5,077,000 4,199,000 3,253,000 147,000 7,356,000 
      common stock issued to directors in lieu of cash retainer
    		21,000 9,000 6,000 5,000 6,000           
      repayment of pharmakon term loan principal
    		-46,339,000               
      prepayment premium and fees on pharmakon term loan
    		-1,552,000               
      principal payments on royalty financing obligations
    		-12,450,000               
      withholding taxes paid on stock-based awards
    		-628,000 -866,000 -1,351,000 -3,084,000 -261,000 -1,840,000 -2,350,000         
      principal payments on finance lease liabilities
    		-513,000 -536,000 -516,000 -356,000 -556,000 -402,000 -390,000         
      net cash from financing activities
    		-58,814,000 -73,686,000 529,000 -4,021,000 1,274,000 -1,966,000 -1,048,000 -3,173,000 1,225,000 29,356,000 5,077,000 4,199,000 76,325,000 147,000 7,356,000 
      effect of exchange rates on cash, cash equivalents and restricted cash
    		-468,000 1,359,000 451,000             
      decrease in cash, cash equivalents and restricted cash, including cash classified within current assets held for sale
    		-4,086,000               
      less: cash and cash equivalents classified within current assets held for sale
    		               
      net decrease in cash, and cash equivalents, and restricted cash
    		-3,868,000               
      cash, cash equivalents and restricted cash:
    		               
      beginning of period
    		0 0 106,323,000             
      end of period
    		-3,868,000 -16,956,000 106,881,000             
      reconciliation of cash, cash equivalents and restricted cash:
    		               
      cash and cash equivalents
    		-3,955,000 -17,157,000 105,190,000             
      restricted cash
    		87,000 201,000 291,000             
      restricted cash in other assets
    		0 0 1,400,000             
      total cash, cash equivalents and restricted cash
    		-3,868,000 -16,956,000 106,881,000             
      decrease (increase) in inventory
    		               
      decrease in prepaid expenses and other assets
    		               
      decrease in accounts payable and accrued expenses
    		               
      less: net increase in cash and cash equivalents classified within current assets held for sale
    		               
      non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs
    		  14,058,000 14,036,000 14,530,000 19,601,000 19,440,000 19,517,000 22,351,000 23,719,000 20,216,000 43,799,000 18,394,000 17,722,000 19,003,000 
      receivables
    		  -13,987,000 -7,296,000 -3,317,000 -8,246,000 -3,839,000 -2,970,000 3,843,000 -8,987,000 2,019,000 -7,643,000 -1,484,000 -5,295,000 -7,048,000 
      inventory
    		  -870,000 -2,163,000 -1,520,000 739,000 -1,220,000 907,000 -3,386,000 898,000 131,000 -1,160,000 -3,674,000 -7,235,000 -354,000 
      prepaid expenses and other assets
    		  -132,000 574,000 -1,466,000 1,745,000 1,106,000 710,000 -6,046,000 1,063,000 -2,547,000 -1,451,000 -82,000 1,270,000 -2,320,000 
      accounts payable and accrued expenses
    		  -47,143,000 -2,446,000 -2,830,000 -12,534,000 -44,569,000 19,872,000 -9,264,000 -188,000 -27,226,000 5,279,000 -19,176,000 14,445,000 -22,908,000 
      maturities of investments
    		  76,000,000 58,000,000            
      increase in cash, cash equivalents and restricted cash
    		  558,000             
      supplemental cash flow disclosure:
    		               
      cash paid for interest
    		  9,153,000 10,141,000 10,201,000 5,054,000 4,987,000         
      cash paid for taxes
    		  1,000 378,000 360,000 679,000 186,000         
      taxes withheld on stock-based awards included in accrued expenses
    		  276,000 513,000 56,000 -1,657,000 1,846,000         
      amortization of premium (discount) on investments
    		               
      loss on impairment
    		               
      deferred revenue
    		       -419,000 -1,346,000 570,000 -35,000 -438,000 143,000 111,000 75,000 
      net proceeds from secured term loans
    		       0        
      repayment of athyrium secured term loans principal
    		       0 0       
      prepayment and repayment fees on athyrium secured term loans
    		       0 0       
      payment of debt issuance costs on pharmakon tranche a term loan
    		       0 -262,000       
      decrease in cash, cash equivalents and restricted cash
    		   7,259,000 18,859,000 -5,926,000 -26,316,000  4,700,000 -8,810,000 -149,640,000  -25,676,000 -124,839,000 -108,876,000 
      beginning of year
    		               
      end of year
    		               
      amortization of premium/discount on investments
    		    -2,039,000 -3,493,000 -3,181,000 -3,449,000 -2,597,000 -2,832,000 -1,385,000 -959,000 -730,000 -118,000 30,000 
      purchase of investments
    		    -26,932,000 -112,294,000 -88,009,000  -123,889,000 -84,893,000 -148,637,000  -105,023,000 -101,194,000 -38,066,000 
      net proceeds from pharmakon tranche a term loan
    		               
      effect of exchange rate on cash, cash equivalents, and restricted cash
    		    851,000 -143,000 -340,000  253,000 -317,000 -96,000  -14,000 209,000 40,000 
      cash, cash equivalents and restricted cash at beginning of period
    		    0 0 112,447,000  0 0 306,239,000  0 0 507,734,000 
      cash, cash equivalents and restricted cash at end of period
    		    18,859,000 -5,926,000 86,131,000  4,700,000 -8,810,000 156,599,000  -25,676,000 -124,839,000 398,858,000 
      net proceeds from common stock issued to directors in lieu of cash retainer
    		      11,000         
      gain on extinguishment of debt
    		               
      interest payable
    		               
      sale of common stock
    		               
      net proceeds from royalty financing liabilities
    		               
      effects of exchange rates on cash, cash equivalents and restricted cash
    		               
      cash, cash equivalents and restricted cash at beginning of year
    		               
      cash, cash equivalents and restricted cash at end of year
    		               
      inventory obsolescence expense
    		               
      change in fair value of foreign currency derivative
    		               
      (gain) loss on extinguishment of debt
    		               
      acquisition of property and equipment
    		               
      sale of pre-funded warrants
    		               
      proceeds from additional credit facility
    		               
      payment of senior credit facility
    		               
      net proceeds from secured term loan
    		               
      net proceeds from royalty financing obligations
    		               
      realized gain on investments
    		               
      non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs
    		               
      proceeds from senior credit facility
    		               
      cash flows from operating activities
    		               
      non-cash interest expense on royalty financing obligation
    		               
      non-cash paid in-kind interest on secured term loan
    		               
      amortization of debt issuance costs
    		               
      cash flows from investing activities
    		               
      cash flows from financing activities
    		               
      effect of exchange rate on cash and cash equivalents
    		               
      operating activities
    		               
      investing activities
    		               
      financing activities
    		               
      accounts payable, accrued expenses and other liabilities
    		               
      operating activities:
    		               
      gain on disposal of property and equipment
    		               
      net cash from operating activities:
    		               
      investing activities:
    		               
      net cash from investing activities:
    		               
      financing activities:
    		               
      net proceeds from royalty financing obligation
    		               
      increase in lease financing obligation
    		               
      net cash from financing activities:
    		               
      net cash provided by financing activities
    		               
      proceeds from sale of property and equipment
    		               
      deferred collaboration expense
    		               
      decrease in lease financing obligation
    		               
      depreciation, amortization, and impairment
    		               
      (gain) loss on disposal of property and equipment
    		               
      change in restricted cash
    		               
      increase in cash and cash equivalents
    		               
      cash and cash equivalents at beginning of year
    		               
      cash and cash equivalents at end of year
    		               
      loss on disposal of property and equipment
    		               
      payment of foreign currency derivative collateral
    		               
      cash and cash equivalents at beginning of period
    		               
      cash and cash equivalents at end of period
    		               
      net cash provided (used) in investing activities:
    		               
      decrease in cash and cash equivalents
    		               
      exercise of stock options
    		               
      employee stock purchase plan sales
    		               
      receipt of foreign currency derivative collateral
    		               
      acquisitions of furniture and equipment
    		               
      gain on disposal of furniture and equipment
    		               
      acquisition of furniture and equipment
    		               
      proceeds from sale of furniture and equipment
    		               
      receipt (payment) of foreign currency derivative collateral
    		               
      deferred collaboration revenue
    		               
      (payment) receipt of foreign currency derivative collateral
    		               
      receivables from collaborations
    		               
      proceeds from sale furniture and equipment
    		               
      purchases of treasury stock
    		               
      issuance of non-recourse notes payable
    		               
      interest reserve
    		               
      prepaid expenses and other current assets
    		               
      inventories
    		               
      deferred rent
    		               
      purchases of marketable securities
    		               
      sales and maturities of marketable securities
    		               
      common stock issuance costs
    		               
      debt issuance costs
    		               
      sale of common stock, net of issuance costs
    		               
      depreciation, amortization and impairment
    		               
      purchases of patents and licenses
    		               
      maturities of marketable securities
    		               
      cash and equivalents at beginning of year
    		               
      depreciation and amortization of furniture and equipment
    		               
      impairment of furniture and equipment
    		               
      amortization of patents and licenses
    		               
      impairment of patents and licenses
    		               
      accounts payable
    		               
      accrued expenses
    		               
      accrued vacation
    		               
      receivable from collaboration
    		               
      non-monetary compensation
    		               
      changes in operating assets and liabilities
    		               
      purchases of furniture and equipment
    		               
      proceeds from sale of common stock
    		               
      non-monetary compensation cost
    		               
      deferred expense
    		               
      purchase of marketable securities
    		               
      principal payments of debt and capital lease obligations
    		               
      employee stock purchase plan stock sales
    		               
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.